sellWeak cluster of 510b5-1 plan
Adam Woodrow sold $20k of PRTK
President & Chief Commercial at Paratek Pharmaceuticals, Inc.. 10,073 shares at an average of $1.97, traded Dec 12, 2022, filed Dec 14, 2022.
Warning score
15Value
$20k
10,073 shares
Holdings after
635,534
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- 0Trade size$20k at market
- 0Share of holdings soldSold 1.6% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000904454-22-000629, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2022 | SOpen-market sale Common Stock10b5-1 | -3,820 | $1.98 | $7,564 | 641,787 | Dec 14, 2022 |
| Dec 13, 2022 | SOpen-market sale Common Stock10b5-1 | -6,253 | $1.96 | $12k | 635,534 | Dec 14, 2022 |
Related signals
Other insiders at Paratek Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Paratek Pharmaceuticals, Inc. | Michael Bigham Exec. Chairman of the Board | $31k 15,750 shares | -1% | |
| 10Weak | Paratek Pharmaceuticals, Inc. | Randall B. Brenner Chief Development & Regulatory | $9,033 4,539 shares | -1% | |
| 10Weak | Paratek Pharmaceuticals, Inc. | William M. Haskel CLO, General Counsel & Sec. | $14k 7,007 shares | -2% | |
| 26Weak | Paratek Pharmaceuticals, Inc. | Evan Loh CEO | $47k 23,489 shares | -2% | |
| 15Weak | Paratek Pharmaceuticals, Inc. | Adam Woodrow President & Chief Commercial | $13k 6,750 shares | -1% | |
| 25Weak | Paratek Pharmaceuticals, Inc. | Michael Bigham Exec. Chairman of the Board | $101k 51,375 shares | -4% | |
| 17Weak | Paratek Pharmaceuticals, Inc. | Randall B. Brenner Chief Development & Regulatory | $58k 29,282 shares | -8% | |
| 18Weak | Paratek Pharmaceuticals, Inc. | William M. Haskel CLO, General Counsel & Sec. | $75k 37,994 shares | -9% | |
| 32Weak | Paratek Pharmaceuticals, Inc. | Evan Loh CEO | $196k 99,750 shares | -8% | |
| 15Weak | Paratek Pharmaceuticals, Inc. | Michael Bigham Exec. Chairman of the Board | $21k 6,000 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.